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BACKGROUND
Prostate cancer is a heterogeneous disease, but current treatments are not based 
on molecular stratification. We hypothesized that metastatic, castration-resistant 
prostate cancers with DNA-repair defects would respond to poly(adenosine diphos-
phate [ADP]–ribose) polymerase (PARP) inhibition with olaparib.
METHODS
We conducted a phase 2 trial in which patients with metastatic, castration-resis-
tant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice 
a day. The primary end point was the response rate, defined either as an objective 
response according to Response Evaluation Criteria in Solid Tumors, version 1.1, 
or as a reduction of at least 50% in the prostate-specific antigen level or a confirmed 
reduction in the circulating tumor-cell count from 5 or more cells per 7.5 ml of 
blood to less than 5 cells per 7.5 ml. Targeted next-generation sequencing, exome 
and transcriptome analysis, and digital polymerase-chain-reaction testing were 
performed on samples from mandated tumor biopsies.
RESULTS
Overall, 50 patients were enrolled; all had received prior treatment with docetaxel, 
49 (98%) had received abiraterone or enzalutamide, and 29 (58%) had received 
cabazitaxel. Sixteen of 49 patients who could be evaluated had a response (33%; 
95% confidence interval, 20 to 48), with 12 patients receiving the study treatment 
for more than 6 months. Next-generation sequencing identified homozygous dele-
tions, deleterious mutations, or both in DNA-repair genes — including BRCA1/2, 
ATM, Fanconi’s anemia genes, and CHEK2 — in 16 of 49 patients who could be 
evaluated (33%). Of these 16 patients, 14 (88%) had a response to olaparib, including 
all 7 patients with BRCA2 loss (4 with biallelic somatic loss, and 3 with germline 
mutations) and 4 of 5 with ATM aberrations. The specificity of the biomarker suite 
was 94%. Anemia (in 10 of the 50 patients [20%]) and fatigue (in 6 [12%]) were 
the most common grade 3 or 4 adverse events, findings that are consistent with 
previous studies of olaparib.
CONCLUSIONS
Treatment with the PARP inhibitor olaparib in patients whose prostate cancers 
were no longer responding to standard treatments and who had defects in DNA-
repair genes led to a high response rate. (Funded by Cancer Research UK and others; 
ClinicalTrials.gov number, NCT01682772; Cancer Research UK number, CRUK/11/029.)
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Prostate cancer is the most common cancer in men and the sixth leading cause of death from cancer among men through-
out the world.1 The interpatient molecular het-
erogeneity of this disease is well recognized; 
however, treatment to date has not been molecu-
larly stratified.2,3 It would be useful to identify 
predictive biomarkers in order to provide more 
precise treatment for this disease.4
Metastatic, castration-resistant prostate can-
cer can have genomic aberrations that interfere 
with DNA repair.3,5 Some of these aberrations 
have been associated with sensitivity to platinum 
and poly(adenosine diphosphate [ADP]–ribose) 
polymerase (PARP) inhibitors, suggesting that 
treatment with a PARP inhibitor may exploit a 
synthetic lethal interaction.6-9 PARP is involved 
in multiple aspects of DNA repair, and the PARP 
inhibitor olaparib (Lynparza, AstraZeneca) has 
recently been approved for treating ovarian can-
cers with BRCA1/2 mutations.10,11
PARP inhibition has durable antitumor activ-
ity in men with metastatic, castration-resistant 
prostate cancer and deleterious germline BRCA2 
mutations, a disease subset associated with a 
poor prognosis.8,12-14 We hypothesized that 
olaparib would have antitumor activity in spo-
radic cases of metastatic, castration-resistant 
prostate cancer with DNA-repair defects. In this 
clinical trial (TOPARP-A, Trial of PARP Inhibi-
tion in Prostate Cancer), we treated men with 
metastatic, castration-resistant prostate cancer 
with olaparib, obtaining fresh tumor-biopsy 
samples from all patients to conduct biomarker 
studies from both germline and somatic DNA, 
including exome and transcriptome sequencing, 
in order to elucidate the genomic aberrations, if 
any, associated with sensitivity to PARP inhibi-
tion in this disease.
Me thods
Study Oversight
This investigator-initiated study was designed by 
the TOPARP Protocol Development Group (see 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org) and was 
cosponsored by the Institute of Cancer Research 
and the Royal Marsden NHS Foundation Trust. 
AstraZeneca provided olaparib free of cost and 
some funding in collaboration with the National 
Institute for Health Research Cancer Research 
Network but had no other role in the study. The 
study was approved by the research ethics com-
mittee at each participating site and by the 
Medicines and Healthcare Products Regulatory 
Agency. It was overseen by an independent steer-
ing committee and an independent data moni-
toring committee. Data were collated and ana-
lyzed by the Clinical Trials and Statistical Unit at 
the Institute of Cancer Research and were inter-
preted by all the authors. The manuscript was 
written by the first and last authors. All the au-
thors reviewed the manuscript and vouch for the 
accuracy and completeness of the data and for 
the fidelity of the study to the protocol, which is 
available at NEJM.org.
Patients
Eligible patients had histologically confirmed, 
metastatic, castration-resistant prostate cancer 
with progression after one or two regimens of 
chemotherapy. Additional eligibility criteria in-
cluded an Eastern Cooperative Oncology Group 
(ECOG) performance-status score of 0 to 2 (on a 
scale of 0 to 5, with 0 indicating no symptoms 
and higher scores indicating increasing disabil-
ity); no prior exposure to platinum, cyclophos-
phamide, mitoxantrone, or PARP inhibitors; 
documentation of cancer progression on the 
basis of Prostate Cancer Working Group 2 
(PCWG2) criteria (see the Supplementary Appen-
dix),15 Response Evaluation Criteria in Solid Tu-
mors (RECIST), version 1.1, or both sets of cri-
teria16; adequate organ function; and 5 or more 
circulating tumor cells per 7.5 ml of blood. 
Complete eligibility criteria are available in the 
Supplementary Appendix. All patients provided 
written informed consent.
Study Design, Treatment, and End Points
TOPARP-A was an open-label, single-group, two-
stage, phase 2, multisite study (Fig. S1 in the 
Supplementary Appendix). All the patients were 
treated with olaparib tablets at a dose of 400 mg 
twice a day until the occurrence of radiologic 
progression, unequivocal clinical progression, 
unacceptable side effects, withdrawal of con-
sent, or death. Dose-modification guidelines for 
managing toxic effects were implemented.
The primary end point was the response rate. 
A response was defined as any of the following: 
a response according to RECIST, version 1.1; a 
reduction in the prostate-specific antigen (PSA) 
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level of 50% or more; or a conversion in the 
circulating tumor-cell count, which is indicated 
by a reduction in the number of circulating tu-
mor cells from 5 or more per 7.5 ml of blood at 
baseline to less than 5 per 7.5 ml during treat-
ment, with a confirmatory assessment at least 4 
weeks later. Secondary end points included ra-
diologic progression–free survival (defined as 
the time to the first evidence of two new lesions 
on a bone scan plus two additional lesions on a 
confirmatory scan, as specified by PCWG2 crite-
ria; progression according to RECIST, version 
1.1; or death), progression-free survival, overall 
survival, time to PSA progression (a 25% in-
crease in the PSA level), proportion of patients 
with conversion of the circulating tumor-cell 
count, and safety of olaparib and adverse events.
Assessments
Disease assessments performed at baseline and 
every 12 weeks included computed tomographic 
(CT) studies or magnetic resonance imaging 
(MRI) and whole-body bone scanning, PSA mea-
surements, and circulating tumor-cell counts. 
Additional circulating tumor-cell counts were 
performed after 1, 2, 4, and 8 weeks of treat-
ment. Radiologic evaluations were subject to 
retrospective central review by radiologists who 
were unaware of the outcome data. Safety was 
assessed by monitoring adverse events, graded 
according to Common Terminology Criteria for 
Adverse Events (CTCAE), version 4.0 (see the 
Supplementary Appendix). Samples from proto-
col-specified biopsies were obtained from all 
patients during screening and in the first 4 
weeks of treatment.
Biomarker Studies
All biomarker studies were prospectively planned. 
Whole-exome sequencing and transcriptome 
studies were performed on DNA from fresh-
frozen tumor-biopsy samples obtained before 
treatment; germline whole-exome sequencing 
was performed on DNA from saliva samples. 
These studies were conducted at the University 
of Michigan as previously described.3,17 Targeted 
next-generation sequencing studies were con-
ducted at the Institute of Cancer Research18,19; 
libraries were constructed with the use of the 
GeneRead DNAseq Panel (Qiagen) and run on a 
MiSeq sequencer (Illumina). Copy-number data 
were validated by means of droplet digital poly-
merase-chain-reaction (PCR) testing with the 
use of the QX100 Droplet Digital PCR System 
(Bio-Rad).19 Circulating tumor-cell counts were 
performed with the use of CellSearch (Janssen 
Diagnostics).20 For the purpose of correlating the 
results of next-generation sequencing with the 
response to treatment, patients were classified 
as positive or negative for genomic defects in 
DNA-repair genes. A patient was considered to 
be biomarker-positive if a homozygous deletion 
or deleterious mutation was identified in a gene 
reported to be involved either in DNA damage 
repair or sensitivity to PARP inhibition.21-23 PTEN 
and ERG protein expression was determined by 
means of immunohistochemical assessment24 
(for details, see the Supplementary Appendix).
Statistical Analysis
A cohort of 45 patients was planned for TOPARP-
A, which had a two-stage, phase 2 design 
(30 patients in stage 1, and 15 in stage 2), with 
a response rate of 5% or less for the null hypoth-
esis and a response rate of more than 20% for 
the alternative hypothesis (at an alpha level of 
0.02 and a beta level of 0.10). Safety analyses 
were descriptive and included all patients receiv-
ing at least one dose of olaparib. Analyses of 
response end points included all patients who 
could be evaluated for a response, with correla-
tive biomarker-response analyses performed for 
all such patients. Statistical analyses were con-
ducted with the use of Stata software, version 13 
(StataCorp), on a snapshot of the data taken on 
April 24, 2015, as preplanned, when all patients 
had either discontinued treatment or received 
treatment for more than 6 months.
A two-sided exact binomial 95% confidence 
interval was calculated for the response rate. 
Percentage changes in PSA levels and circulating 
tumor-cell counts were represented in waterfall 
plots and longitudinal time plots. Time-to-event 
end points (radiologic progression–free, pro-
gression-free, and overall survival), measured 
from the time of study entry, were assessed by 
means of Kaplan–Meier methods. The associa-
tion of biomarkers with treatment response was 
tested by means of the chi-square test or Fisher’s 
exact test, as appropriate. Univariable and mul-
tivariable logistic-regression models were used 
to calculate the unadjusted and adjusted odds 
ratios for a response. For the association of 
time-to-event end points with biomarker status, 
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a log-rank test was used, and hazard ratios were 
calculated with the use of a Cox proportional-
hazards model (with a hazard ratio of less than 
1.00 indicating a reduced risk of events in the 
biomarker-positive subgroup). The proportional-
hazards assumption was tested with the use of 
Schoenfeld residuals.
R esult s
Study Patients
From July 2012 through September 2014, a total 
of 50 patients (30 in stage 1 and 20 in stage 2 of 
the study) were enrolled at seven centers. All 
patients received at least one dose of olaparib. 
One patient was lost to follow-up after the first 
week; the data monitoring committee decided 
that this patient could not be evaluated for a 
response (Fig. S2 in the Supplementary Ap-
pendix). At the time of data cutoff, 35 of the 
50 patients (70%) had died, with 4 patients re-
maining in the study after at least 40 weeks of 
therapy. The median overall survival was 10.1 
months (interquartile range, 5.1 to 15.6), with a 
median follow-up of 14.4 months (range, 1.4 to 
21.9). Table 1 summarizes the baseline charac-
teristics of the patients.
Antitumor Activity
Sixteen of the 49 patients who could be evalu-
ated had a response to olaparib on the basis of 
the composite definition of response specified 
in the study protocol (response rate, 33%; 95% 
confidence interval, 20 to 48). The median dura-
tion of treatment for the 16 patients who had a 
response was 40 weeks, with 12 patients receiv-
ing olaparib for more than 6 months and 4 pa-
tients receiving it for more than 12 months. 
Overall, 11 of the 49 patients (22%) had reduc-
tions in the PSA level of 50% or more. The me-
dian circulating tumor-cell count at baseline was 
37 cells per 7.5 ml of blood (interquartile range, 
14 to 110); 14 of the 49 patients (29%) had a 
confirmed reduction in the circulating tumor-
cell count to less than 5 cells per 7.5 ml. Of the 
49 patients who could be evaluated, 32 (65%) 
had measurable disease at baseline according to 
RECIST, version 1.1; 6 of these patients (19%) 
had a confirmed radiologic partial response 
(Table 2).
Defects in DNA Damage-Repair Genes
Paired samples from tumor biopsies performed 
before treatment and during treatment were 
available for all patients participating in the 
study; 28 patients underwent bone marrow biop-
sies, and 22 underwent imaging-guided biopsies 
Characteristic Value
Age — yr
Median 67.5
Range 40.8–79.3
Time since initial diagnosis of prostate  
adenocarcinoma — yr
Median 5.0
Interquartile range 3.4–7.9
Metastatic disease at initial diagnosis — no. (%) 23 (46)
Time since confirmation of CRPC — yr
Median 2.2
Interquartile range 1.7–3.9
PSA — ng/ml
Median 349.5
Interquartile range 153–806
CTC count — no. of cells/7.5 ml of blood
Median 37
Interquartile range 14–110
ECOG performance-status score — no. (%)†
0  9 (18)
1 35 (70)
2  6 (12)
Received prior regimens for CRPC — no. (%)
2 3 (6)
3  7 (14)
≥4 40 (80)
Received prior treatments — no. (%)
Radical prostatectomy or radiotherapy 25 (50)
Castration (chemical or surgical)  50 (100)
Abiraterone acetate 48 (96)
Enzalutamide 14 (28)
Docetaxel  50 (100)
Cabazitaxel 29 (58)
Radium-223 1 (2)
*  CRPC denotes castration-resistant prostate cancer, CTC circulating tumor-cell, 
and PSA prostate-specific antigen.
†  The Eastern Cooperative Oncology Group (ECOG) performance-status score 
ranges from 0 to 5, with 0 indicating no symptoms and higher scores indicat-
ing increasing disability.
Table 1. Baseline Characteristics of the 50 Study Patients.*
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of nodal or visceral metastases. Of the 49 pa-
tients who could be evaluated for a response, 43 
had tumor-biopsy material that was suitable for 
next-generation sequencing. For the other 6 pa-
tients, archival tumor samples obtained at diag-
nosis were analyzed.
Overall, 16 patients (33%) had tumor aberra-
tions in DNA-repair genes (Fig. 1). BRCA2 aber-
rations were detected in 7 patients: 2 had so-
matic homozygous deletions, 2 had a combination 
of somatic mutations and loss of heterozygosity, 
and 3 had a previously unidentified germline 
pathogenic mutation with somatic loss of the 
second allele. Five other patients had tumors 
with ATM aberrations. Three of these patients 
had germline mutations predicted to cause trun-
cation of the ATM protein, and 2 of the 3 also 
had aberrant alleles in somatic DNA (1 with loss 
of heterozygosity and 1 with a missense muta-
tion in the kinase domain–coding region of 
ATM). The other 2 patients had ATM mutations 
with no germline events: 1 had a frameshift 
mutation (p.V2288fs*1) predicted to cause trun-
cation before the C-terminal phosphoinositide 
3-kinase (PI3K) catalytic domain (normally 
formed by amino acid residues 2712 through 
2962), as well as ATM domains required for p53 
activation and the response to DNA damage,25,26 
and 1 had a missense mutation (p.N2875H) 
within the PI3K catalytic domain of ATM.27 Ho-
mozygous somatic deletions of BRCA1 or CHEK2 
occurred with FANCA deletion in 3 patients. A 
somatic frameshift mutation in PALB2 (partner 
and localizer of BRCA2) was also detected in a 
patient with a heterozygous PALB2 deletion. Fi-
nally, biallelic somatic aberrations in histone 
Patient 
No.
Maximum  
PSA Decline
Measurable 
Disease at 
Baseline
Best  
Radiologic 
Response*
Confirmed CTC 
Conversion CTC Count
Duration of 
Treatment
Biomarker 
Status
Baseline
Maximum 
Decline
%
no./7.5 ml  
of blood % wk
1 85 No No 87 100 73 Positive
5 51 No Yes 24 100 58 Positive
6 29 Yes SD Yes 105 97.1 16† Positive
8 47 No Yes 38 94.7 62 Positive
11 No decline Yes PD Yes 6 83.3 12 Negative
14 83 No Yes 102 100 36 Positive
15 80 Yes PR Yes 18 100 36 Positive
16 88 Yes PR Yes 5 100 40‡ Negative
17 95 Yes PR Yes 8 100 24 Positive
20 88 Yes PR NE <5 100 48 Positive
26 No decline No Yes 12 100 19§ Positive
30 70 No Yes 100 100 44‡ Positive
35 96 Yes PR Yes 513 100 40‡ Positive
36 59 No Yes 22 100 57 Positive
39 68 Yes PR Yes 24 100 44‡ Positive
48 No decline Yes SD Yes 9 100 39 Positive
*  Best radiologic response was assessed in patients with measurable disease at baseline, according to Response Evaluation Criteria in Solid 
Tumors (RECIST), version 1.1. NE denotes not evaluated, PD progressive disease, PR partial response, and SD stable disease.
†  The patient required repeated reductions in the dose of olaparib, to 200 mg twice a day.
‡  The patient was still receiving treatment at the time of data cutoff.
§  Treatment was discontinued because of an adverse event.
Table 2. Changes in PSA Levels and CTC Counts, Best Radiologic Response, Duration of Treatment, and Biomarker Status for the 16 Patients 
with a Treatment Response.
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deacetylase 2 (HDAC2), which has a role in ATM 
function and the response to DNA damage,28-30 
were identified in 1 patient.
Overall, patients with aberrations in DNA-
repair genes had a significantly higher response 
rate in unadjusted and adjusted analyses (P<0.001 
Figure 2. Antitumor Activity of Olaparib and Association with Defects in DNA-Repair Genes, According to Biomarker Status.
Panels A and B show radiologic progression–free survival and overall survival curves, respectively, for patients with genomic defects in 
DNA-repair genes (biomarker-positive group) and patients without such defects (biomarker-negative group). The hazard ratio for radio-
logic progression in the biomarker-positive group as compared with the biomarker-negative group was 0.24 (95% confidence interval 
[CI], 0.11 to 0.50), and the hazard ratio for death was 0.47 (95% CI, 0.22 to 1.02). Panels C and D show mean percentage changes in 
prostate-specific antigen (PSA) levels and circulating tumor-cell (CTC) counts, respectively, over the course of treatment in the biomarker-
positive and biomarker-negative groups.
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in a multivariable logistic-regression model for 
response) (Tables S2 through S5 in the Supple-
mentary Appendix); 14 of 16 biomarker-positive 
patients (88%) had a response to olaparib. Con-
versely, only 2 of 33 biomarker-negative patients 
(6%) were classified as having a response (sensi-
tivity, 88%; specificity, 94%). Radiologic progres-
sion–free survival was significantly longer in the 
biomarker-positive group than in the biomarker-
negative group (median, 9.8 vs. 2.7 months; 
P<0.001 by the log-rank test) (Fig. 2). Overall 
survival was also prolonged in the biomarker-
positive group (median, 13.8 months, vs. 7.5 
months in the biomarker-negative group; P = 0.05 
by the log-rank test), even though established 
prognostic factors were balanced between the 
two groups (Table S6 in the Supplementary Ap-
pendix).
All seven patients with BRCA2 loss had PSA 
levels that fell by 50% or more from baseline; of 
these seven patients, all five with measurable 
disease also had a radiologic partial response 
(Fig. 3). Four of the five patients with deleterious 
ATM mutations had a response to olaparib, in-
cluding all three patients with DNA mutations 
predicted to cause loss of the kinase catalytic 
domain of ATM but with no defects in the sec-
ond ATM allele.
An additional three patients who were classi-
fied as biomarker-positive had a response to 
olaparib. Patient 26, who had a somatic homozy-
gous deletion of both BRCA1 and FANCA, had a 
response, with a reduction in the circulating 
tumor-cell count from 12 to 0 cells per 7.5 ml; 
olaparib was discontinued prematurely after 
19 weeks because of myelosuppression with 
radiologic stable disease (Table 2). Patient 48, 
whose tumor had biallelic PALB2 aberrations, 
had a durable response that lasted for 39 weeks. 
The third patient with a response (Patient 8), 
who had biallelic somatic aberrations in HDAC2, 
received the study treatment for 62 weeks. His 
transcriptome revealed low HDAC1 and HDAC2 
messenger RNA expression (Fig. S4 in the Sup-
plementary Appendix). Conversely, a patient with 
defective mismatch DNA repair due to biallelic 
MLH3 loss with somatic homozygous deletion of 
FANCA and CHEK2 did not have a response to 
therapy, nor did the fifth patient with mutant 
ATM, who had radiologic progression of the liver 
metastases and an increase in the PSA level at 
the first response assessment.
Finally, in two other patients categorized as 
having a response according to trial criteria, 
tumor-exome sequencing identified no genomic 
defects fulfilling the study definition of defec-
tive DNA repair. However, one of the two pa-
tients (Patient 11) had little evidence of a true 
response, with a drop in circulating tumor-cell 
counts from 6 cells to 1 cell per 7.5 ml and ra-
diologic progression at 12 weeks. The other pa-
tient (Patient 16) had a clear radiologic response 
according to RECIST, as well as an 86% reduc-
tion in the PSA level. This patient’s tumor had 
monoallelic deletions of both BRCA2 and PALB2, 
with no detectable loss of the other allele evident 
on whole-exome sequencing.
Safety
The median duration of olaparib treatment was 
12 weeks (interquartile range, 11 to 24). The 
average delivered-dose intensity was 87%. The 
most commonly reported adverse events that 
developed during treatment are summarized in 
Table S7 in the Supplementary Appendix. Grade 
3 or 4 drug-related events were primarily anemia 
Figure 3 (facing page). Radiologic Evidence of Tumor 
Responses to Olaparib at Week 12.
Panel A shows CT scans of the chest, obtained in the 
lung and soft-tissue window settings, from a 61-year-
old man with metastatic, castration-resistant prostate 
cancer (Patient 39) who had a response to olaparib; 
there was shrinkage of the lung and nodal (arrows) 
metastatic deposits after 12 weeks of therapy (right), 
as compared with baseline (left). Whole-exome sequenc-
ing showed a somatic homozygous deletion of BRCA2. 
Panel B shows CT scans with coronal reconstruction  
in a 70-year-old man with a somatic BRCA2 frameshift 
insertion (p.Y2154fs*21) and somatic deletion of the 
second allele (Patient 20). The scans show the response 
in the mediastinal and abdominal lymph nodes (arrows). 
The patient received treatment for a total of 48 weeks. 
Panel C shows multiparametric whole-body MRI scans, 
including diffusion-weighted imaging, with coronal 
three-dimensional reconstruction and selected axial 
images in a 79-year-old man (Patient 1) who had a re-
sponse to olaparib, with an 85% reduction in the PSA 
level. The patient received treatment for a total of 73 
weeks. The images show reduction in the water con-
tent within the skeletal metastasis, which in conjunction 
with other findings on imaging would be consistent with 
tumor regression during therapy (right), as compared 
with baseline (left). Next-generation sequencing of the 
baseline bone marrow–biopsy specimen revealed a so-
matic missense mutation within the ATM phosphoino-
sitide 3-kinase catalytic domain (p.N2875S), with no 
evidence of genomic loss of the second allele and with 
maintenance of ATM expression on immunohistochem-
ical assessment.
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(in 10 of the 50 patients [20%]), fatigue (in 6 pa-
tients [12%]), leukopenia (in 3 patients [6%]), 
thrombocytopenia (in 2 patients [4%]), and neu-
tropenia (in 2 patients [4%]). Overall, 13 patients 
(26%) required a reduction in the dose of olapa-
rib to 300 mg twice a day; anemia was the most 
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common indication for the dose reduction (in 
7 patients). These episodes of anemia were con-
sidered to be largely drug-related, although most 
of the patients with anemia had extensive bony 
disease involvement; the median baseline hemo-
globin level was 11.2 g per deciliter. Three of the 
13 patients required a second dose reduction, to 
200 mg of olaparib twice a day. Olaparib was 
permanently discontinued in 3 patients (6%) 
because of adverse events.
Discussion
The results of this clinical trial suggest that a 
common subset of metastatic prostate cancers 
can be molecularly stratified for treatment. This 
subset, characterized by defects in DNA repair, 
accounts for approximately 25 to 30% of all 
sporadic, castration-resistant prostate cancers.3,17 
The protocol for our therapeutic trial mandated 
the acquisition of fresh tumor-biopsy samples 
from patients with metastatic, castration-resis-
tant prostate cancer in order to identify predic-
tive biomarkers. Our findings suggest that this 
approach is feasible and that next-generation 
sequencing analyses of tumor-biopsy samples 
can increase our understanding of treatment re-
sponses. Additional studies are needed to assess 
whether the frequency of DNA-repair defects in 
patients with untreated prostate cancer is identi-
cal to the frequency in patients with castration-
resistant prostate cancer.
Evidence for the antitumor activity of olaparib 
in this study cohort includes concurrent falls in 
PSA levels and circulating tumor-cell counts, 
with radiologic responses on CT scans and re-
gression of bone disease on serial whole-body 
MRI scans (Fig. 3). Responses to treatment com-
monly lasted for more than 6 months and were 
associated with prolonged radiologic progression–
free survival and impressive falls in circulating 
tumor-cell counts; however, we cannot yet deter-
mine whether olaparib improves overall survival 
among patients with metastatic, castration-resis-
tant prostate cancer and DNA-repair defects.20,31
Using a high-throughput, next-generation 
sequencing assay, we detected multiple types 
of genomic aberrations associated with PARP- 
inhibitor sensitivity. Alterations were observed 
in BRCA2, ATM, BRCA1, PALB2, CHEK2, FANCA, 
and HDAC2, all of which have been reported to 
have a synthetic lethal interaction with PARP 
inhibition.21,22
BRCA2 loss is well recognized in prostate 
cancer.3,5 Of the seven patients in our study who 
had BRCA2 genomic aberrations, three also had 
previously unknown deleterious germline muta-
tions in BRCA2, for an overall prevalence of 6% 
in our cohort of unselected patients. This find-
ing is in keeping with emerging data17 and sug-
gests that the prevalence of germline BRCA2 
mutations in castration-resistant prostate cancer 
has been underestimated.32 We also identified 
truncating ATM germline mutations in three 
patients (6%) in this cohort of patients with ad-
vanced prostate cancers. Further work is needed 
to determine the relevance of these findings.
A notable finding of this study is the re-
sponse to olaparib in patients whose tumors had 
monoallelic ATM aberrations with mutations af-
fecting the kinase catalytic domain, despite the 
continued presence of the second allele and ATM 
protein expression on immunohistochemical as-
sessment. Multiple studies have described how 
the loss of one kinase domain can alter ATM 
protein function.33-35 A proposed explanation is 
that the mutated ATM is dominant negative, but 
ATM haploinsufficiency has not been ruled 
out.36 Aberrations in multiple other DNA repair 
genes associated with PARP-inhibitor sensitivity 
may be present at a low frequency in metastatic, 
castration-resistant prostate cancer, as reported 
in other cancers.21,37 We observed clinical re-
sponses to olaparib in patients with metastatic, 
castration-resistant prostate cancer and defective 
PALB2 or HDAC2. HDAC inhibition has been re-
ported to result in sensitivity to PARP inhibi-
tion,28,38 but the clinical relevance of HDAC ge-
nomic loss is not known.
Platinum-based chemotherapy is generally 
not used for the treatment of metastatic, castra-
tion-resistant prostate cancer, since phase 3 
studies have failed to show a survival benefit in 
unselected patients. Nevertheless, responses to 
single-agent chemotherapy with a platinum ana-
logue such as satraplatin have been reported.39 
Considering the mechanisms of action of plati-
num and data emerging from studies of ovarian 
cancer in which platinum and PARP-inhibitor 
sensitivity were correlated with defects in ho-
mologous recombination DNA repair,40,41 we hy-
pothesize that the DNA-repair defects we are 
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reporting in metastatic, castration-resistant pros-
tate cancer may be associated with platinum 
sensitivity.
In conclusion, we report that PARP inhibition 
has antitumor activity in sporadic cases of meta-
static, castration-resistant prostate cancer and 
that these responses are associated with DNA-
repair defects in tumor cells that can be identi-
fied through next-generation sequencing assays.
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